Want to see CH:MEDX full AI Analyst Report?
Top Page
medmix AG
(MEDX)
Select Model
Select Model
Rating:53Neutral
Price Target:
CHF9.50
▲(16.00% Upside)
Action:Reiterated
Date:08/06/26
Overall score reflects mixed fundamentals with improving but still thin profitability and declining recent revenue, partially supported by positive (though volatile) cash generation. Technicals are moderately supportive near-term but show overbought risk, while valuation is a major drag due to an extremely high P/E and only a modest dividend yield.
Positive Factors
Recurring consumables revenue
medmix's core sales include consumable mixers, nozzles and tips that are used repeatedly in customers' production and clinical workflows. That recurring consumables demand supports predictable revenue streams, reduces reliance on one-time equipment sales, and underpins durable topline resilience.
Negative Factors
Revenue decline / soft demand
Top-line has stalled and declined recently, signalling softer end-market demand or lost volumes. Sustained revenue weakness impairs scale economics, limits operating leverage and makes durable margin expansion and consistent earnings growth more difficult over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables revenue
medmix's core sales include consumable mixers, nozzles and tips that are used repeatedly in customers' production and clinical workflows. That recurring consumables demand supports predictable revenue streams, reduces reliance on one-time equipment sales, and underpins durable topline resilience.
Read all positive factors
medmix AG (MEDX) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF364.76M
Dividend Yield1.13%
Average Volume (3M)115.75K
Price to Earnings (P/E)3536.0
Beta (1Y)0.99
Revenue Growth-6.64%
EPS GrowthN/A
CountryCH
Employees2,574
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)<0.01
Shares Outstanding41,262,370
10 Day Avg. Volume183,978
30 Day Avg. Volume115,752
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)1.08
Price to Sales (P/S)1.02
P/FCF Ratio13.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.56
Revenue Forecast (FY)CHF447.29M
medmix AG Business Overview & Revenue Model
Company Description
Established in 1922 and headquartered in Zug, Switzerland, Medmix AG stands as a global leader in innovating, manufacturing, and distributing high-precision devices and services. These solutions are meticulously engineered for the controlled mixin...
How the Company Makes Money
medmix makes money primarily by selling engineered mixing and dispensing products and solutions to business customers and, where applicable, to medical/healthcare customers. Key revenue streams include: (1) Product sales of consumables and compone...
medmix AG Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
58
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 437.00M | 448.00M | 483.90M | 486.60M | 477.10M | 457.30M |
| Gross Profit | 160.50M | 161.90M | 159.70M | 157.70M | 175.40M | 181.20M |
| EBITDA | 78.40M | 79.70M | 67.60M | 68.40M | 68.30M | 110.60M |
| Net Income | 100.00K | 6.40M | -7.40M | 300.00K | 11.60M | 44.00M |
Balance Sheet | ||||||
| Total Assets | 970.50M | 969.30M | 954.20M | 1.01B | 1.11B | 974.40M |
| Cash, Cash Equivalents and Short-Term Investments | 111.30M | 113.90M | 96.20M | 130.60M | 316.80M | 210.00M |
| Total Debt | 319.40M | 330.30M | 323.40M | 349.70M | 473.50M | 320.90M |
| Total Liabilities | 537.70M | 536.50M | 507.50M | 532.40M | 601.10M | 440.50M |
| Stockholders Equity | 425.00M | 425.70M | 436.40M | 465.40M | 504.80M | 533.90M |
Cash Flow | ||||||
| Free Cash Flow | 31.70M | 33.30M | 38.10M | 3.20M | 9.00M | 55.40M |
| Operating Cash Flow | 59.30M | 67.80M | 86.60M | 56.10M | 47.60M | 87.30M |
| Investing Cash Flow | -31.70M | -40.70M | -51.50M | -80.60M | -57.00M | -3.30M |
| Financing Cash Flow | -25.80M | -36.30M | -48.60M | -153.80M | 116.10M | 111.60M |
medmix AG Technical Analysis
Positive
8.19
Price Trends
8.41
Positive
8.53
Positive
9.40
Negative
Market Momentum
0.22
Negative
70.49
Negative
85.24
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MEDX, the sentiment is Positive. The current price of 8.19 is below the 20-day moving average (MA) of 8.52, below the 50-day MA of 8.41, and below the 200-day MA of 9.40, indicating a neutral trend. The MACD of 0.22 indicates Negative momentum. The RSI at 70.49 is Negative, neither overbought nor oversold. The STOCH value of 85.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:MEDX.
medmix AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | CHF278.37M | 10.12 | 11.74% | 3.63% | -1.24% | -11.13% | |
69 Neutral | CHF188.09M | 13.06 | ― | 2.93% | -2.82% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | CHF364.76M | 3,536.00 | ― | 1.22% | -6.64% | ― | |
53 Neutral | CHF267.65M | -43.14 | ― | ― | -7.68% | -182.03% | |
44 Neutral | CHF401.60M | -2.64 | ― | ― | 19.54% | -288.93% |
* General Sector Average
CH:MEDX
medmix AG
9.15
-1.67
-15.43%
CH:RIEN
Rieter Holding AG
3.19
-3.76
-54.11%
CH:KOMN
Komax Holding AG
58.50
-48.30
-45.22%
CH:MIKN
Mikron Holding AG
16.85
-0.75
-4.26%
CH:STGN
StarragTornos Group AG
37.50
5.57
17.43%
medmix AG Corporate Events
medmix boosts margins and cash flow despite softer H1 revenue
Jul 23, 2026
medmix AG reported a 1.6% organic revenue decline to CHF 214.4 million in the first half of 2026 as weaker demand in its Beauty unit offset growth in Surgery and Industry. Healthcare revenue grew modestly, with strong gains in Surgery and solid de...
Medmix launches customizable FleXa syringe platform to boost dental precision and branding
Jul 9, 2026
Medmix has expanded its dental portfolio with FleXa, a customizable syringe platform designed for single-component dental materials, aimed at giving manufacturers greater precision and branding flexibility in a crowded market. The modular system o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.